Table 3.

Rosiglitazone exposure at entry and hazard ratios for non-melanoma skin cancer

Rosiglitazone use	Unadjusted			Age-sex-adjusted			Fully adjusted*
	HR	95% CI	P	HR	95% CI	P	HR	95% CI	P
Ever users	0.882	(0.773, 1.005)	0.0602	0.908	(0.796, 1.036)	0.1513	0.927	(0.807, 1.066)	0.2865
Duration of therapy (months)
<3.73	1.059	(0.861, 1.304)	0.5862	1.109	(0.901, 1.365)	0.3295	1.119	(0.905, 1.383)	0.2985
3.73-13.77	0.903	(0.730, 1.118)	0.3507	0.941	(0.760, 1.165)	0.5744	0.961	(0.773, 1.196)	0.7243
>13.77	0.703	(0.553, 0.893)	0.0039	0.705	(0.555, 0.896)	0.0043	0.723	(0.566, 0.923)	0.0094
P-trend			0.0072			0.0171			0.0386
Cumulative dose (mg)
<448	1.025	(0.830, 1.265)	0.8221	1.070	(0.867, 1.322)	0.5276	1.081	(0.872, 1.341)	0.4773
448-1752	0.885	(0.713, 1.098)	0.2675	0.912	(0.735, 1.132)	0.4033	0.931	(0.747, 1.161)	0.5270
>1752	0.752	(0.596, 0.948)	0.0157	0.764	(0.606, 0.963)	0.0228	0.783	(0.618, 0.993)	0.0436
P-trend			0.0139			0.0337			0.0743

Referent group: never-users of rosiglitazone; HR: hazard ratio, CI: confidence intervals.

*Adjusted for all variables in Table 1.